title: Effects of switching from agalsidase Beta to agalsidase alfa in 10 patients with anderson-fabry disease.
abstract: Anderson-Fabry disease (AFD) is a multiorgan X-linked lysosomal storage disease that particularly affects the heart, kidneys, and cerebrovascular system. Current treatment is enzyme replacement therapy (ERT) with agalsidase beta (Fabrazyme(®), Genzyme Corporation, Cambridge, MA, USA) or agalsidase alfa (Replagal(®), Shire Human Genetic Therapies AB, Lund, Sweden). It was recommended that patients switch to agalsidase alfa due to a manufacturing shortage of agalsidase beta beginning in June 2009. This study assessed the effect of switching to agalsidase alfa on clinical outcomes in patients with AFD previously treated with agalsidase beta. Ten patients (seven male, three female) with genetically confirmed AFD and at least 48 months' continuous data collected during treatment with agalsidase beta 1 mg/kg every other week were switched to agalsidase alfa 0.2 mg/kg every other week for at least 20 months, with prospective clinical evaluations every 6 months. Pre-switch data was collected retrospectively from patient charts. Cardiac functional parameters were assessed using magnetic resonance imaging. Results showed that renal function was normal (estimated glomerular filtration rate ≥90 mL/min/1.73 m(2)) in 8 of 10 patients prior to agalsidase alfa and generally remained stable after the switch. Cardiac mass decreased significantly (p < 0.05 vs pre-ERT) after agalsidase beta and remained unchanged after switching to agalsidase alfa. Symptoms of pain and health status scores did not deteriorate during agalsidase alfa therapy. Adverse events were mostly mild and infusion related. In conclusion, switching to agalsidase alfa was relatively well tolerated and associated with stable clinical status and preserved renal and cardiac function.
authors: Department of Nephrology, University "Federico II", Via Pansini 5, 80131, Napoli, Italy. antonio.pisani@unina.it.
authors: A
authors: A
authors: Pisani
authors: Department of Cardiovascular and Immunological Science, University "Federico II", Napoli, Italy.
authors: L
authors: L
authors: Spinelli
authors: Department of Nephrology, University "Federico II", Via Pansini 5, 80131, Napoli, Italy.
authors: B
authors: B
authors: Visciano
authors: Department of Nephrology, University "Federico II", Via Pansini 5, 80131, Napoli, Italy.
authors: I
authors: I
authors: Capuano
authors: Department of Nephrology, University "Federico II", Via Pansini 5, 80131, Napoli, Italy.
authors: M
authors: M
authors: Sabbatini
authors: Department of Nephrology, University "Federico II", Via Pansini 5, 80131, Napoli, Italy.
authors: E
authors: E
authors: Riccio
authors: Department of Biomorphological and Functional Science, University "Federico II", Napoli, Italy.
authors: G
authors: G
authors: Messalli
authors: Department of Biomorphological and Functional Science, University "Federico II", Napoli, Italy.
authors: M
authors: M
authors: Imbriaco